Transplant patients with skin cancer get new hope from engineered virus

NCT ID NCT04349436

Ongoing Disease control Sponsor: Replimune, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. Participants receive injections every two weeks for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RP1 (a genetically modified herpes simplex type 1 virus injected directly into tumors)

What this could lead to

If successful, this could offer a new treatment option for transplant patients with advanced skin cancers that are hard to treat.

What could go wrong

This is an early-phase trial with only 69 participants, so results may not apply to everyone. The virus could cause side effects or organ rejection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma cancer carcinoma cutaneous neuroendocrine carcinoma melanoma neoplasm skin neoplasm skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL CARCINOMA CANCER CUTANEOUS SQUAMOUS CELL CARCINOMA LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA MELANOMA MERKEL CELL CARCINOMA

Contacts and locations

Show contact details

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University

Durham, North Carolina, 27708, United States
Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Medical Dermatology Specialists

Phoenix, Arizona, 85006, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Rochester Dermatologic Surgery

New York, New York, 14564, United States
The Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UCSF, Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94143, United States
University of California, Los Angeles

Los Angeles, California, 90024, United States
University of California, San Diego

La Jolla, California, 92093, United States
University of Cincinnati

Cincinnati, Ohio, 45267, United States
University of Colorado Cancer Center School of Medicine

Aurora, Colorado, 80045, United States
University of Miami Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
University of North Carolina Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States
University of Tennessee Medical Center at Knoxville

Knoxville, Tennessee, 37920, United States
University of Texas Southwestern

Dallas, Texas, 75235, United States
Washington University in St. Louis

St Louis, Missouri, 63110, United States